While the expression levels of TGF-β1 and TGF-β2 in adenomyosis remain uncertain, the critical role of the TGF-β signaling pathway in the pathogenesis of adenomyosis and the potential efficacy of TGF-β inhibitors are widely recognized. This evidence concerns the gene TGFB1 and adenomyosis.